JARDIAMET

This brand name is authorized in Australia, New Zealand.

Active ingredients

The drug JARDIAMET contains a combination of these active pharmaceutical ingredients (APIs):

1	Empagliflozin UNII HDC1R2M35U - EMPAGLIFLOZIN
	Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2). Empagliflozin improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption.
	Read more about Empagliflozin
2	Metformin UNII 9100L32L2N - METFORMIN
	Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.
	Read more about Metformin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BD20	Metformin and empagliflozin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs → A10BD19 Linagliptin and empagliflozin
Discover more medicines within A10BD20

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10626G, 10627H, 10633P, 10639Y, 10640B, 10649L, 10650M, 10677Y
NZ	Medicines and Medical Devices Safety Authority	17761, 17762, 17763, 17764, 17765, 17766